-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|April 25, 2025

Closing Perspectives

Author(s)Davida Kruger, MSN, APN-BC, BC-ADM , Jaime Murillo, MD, FACC, FASE , Ian Neeland, MD, FAHA, FACC

Experts discuss how to evaluate the cost-effectiveness of continuous glucose monitoring (CGM) compared to traditional monitoring, considering both clinical and quality outcomes, and what combination of economic and quality data would most effectively support broader CGM adoption across health systems and payer organizations.

Episodes in this series

1 KOL is featured in this series.

EP. 1 CGM: Redefining Type 2 Diabetes Management

EP. 2 Key Benefits of CGM Technology

EP. 2 Key Benefits of CGM Technology

EP. 3 CGM's Impact on Clinical Inertia

EP. 3 CGM's Impact on Clinical Inertia

EP. 4 CGM vs Traditional Monitoring

EP. 4 CGM vs Traditional Monitoring

EP. 5 Understanding CGM Metrics

EP. 5 Understanding CGM Metrics

EP. 6 Health Care System Integration

EP. 6 Health Care System Integration

EP. 7 CGM Coverage and Access

EP. 7 CGM Coverage and Access

EP. 8 Implementation Barriers

EP. 8 Implementation Barriers

EP. 9 Overcoming Access Challenges

EP. 9 Overcoming Access Challenges

EP. 10 Adoption Strategies

EP. 10 Adoption Strategies

EP. 11 The Metro Nashville Public Schools Initiative

EP. 11 The Metro Nashville Public Schools Initiative

EP. 12 Health Care Quality Impact

EP. 12 Health Care Quality Impact

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 14 Long-Term Outcomes Assessment

EP. 14 Long-Term Outcomes Assessment

EP. 15 Closing Perspectives

EP. 15 Closing Perspectives

Video content above is prompted by the following:

How do you evaluate the cost-effectiveness of CGM compared to traditional monitoring when considering both clinical and quality outcomes?
What: combination of economic and quality data would most effectively support broader CGM adoption across health systems and payer organizations?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Unmet Needs and Emerging Mechanisms of Action in Extrapulmonary Neuroendocrine Carcinoma: The Path Toward Better Therapies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression

ByNadege Gunn, MD

July 10th 2026

Screening MASH Upstream: Building a Practical, Scalable Algorithm for the Real World

ByNadege Gunn, MD

July 10th 2026

Experts featured in this series.

Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: July 7th 2026 | Updated: June 16th 2026

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma